Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIFC1 | Q9BW19 | 3/20 | 0.37 |
| ▸ | MME | P08473 | 2/20 | 0.36 |
| ▸ | ANPEP | P15144 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.36 |
| ▸ | FEN1 | P39748 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | SDCBP | O00560 | 3/20 | 0.34 |
| ▸ | SDC2 | P34741 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17834550 | 0.97 | KIFC1 (0.36) | KIFC1MMEANPEPALOX5APFEN1 | |
| SCHEMBL17834504 | 0.96 | MME (0.41) | KIFC1MMEANPEPALOX5APFEN1 | |
| SCHEMBL17834472 | 0.94 | MME (0.36) | KIFC1MMEANPEPMCL1SDCBP | |
| SCHEMBL17834625 | 0.94 | KIFC1 (0.37) | KIFC1MMEANPEPALOX5APFEN1 | |
| SCHEMBL17834840 | 0.93 | ALOX5AP (0.42) | KIFC1ALOX5APFEN1MCL1 | |
| SCHEMBL17834494 | 0.93 | KIFC1 (0.41) | KIFC1MMEANPEPALOX5APFEN1 | |
| SCHEMBL17834905 | 0.93 | SDCBP (0.40) | KIFC1MMEANPEPALOX5APFEN1 | |
| SCHEMBL17834552 | 0.92 | KIFC1 (0.38) | KIFC1MMEANPEPALOX5APFEN1 | |
| SCHEMBL17825401 | 0.91 | MME (0.35) | KIFC1MMEANPEPALOX5APFEN1 | |
| SCHEMBL17834487 | 0.91 | PSMB5 (0.38) | KIFC1MMEANPEPSDCBPSDC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | KIFC1 4738/4885MME 796/4885ANPEP 305/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | KIFC1 4749/4885MME 919/4885ANPEP 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.